Cells: Hemostemix ACP-01 Provides the Scientific Basis for Improving the Longevity and Signal Uptake of Brain Computer Implants
Key Scientific Insights
The Challenge with BCIs: Inflammation, scarring, and programmed cell death undermine performance over timeImplantable electrodes within the brain have enabled remarkable achievements—e.g., paralyzed individuals playing chess and blind individuals recognizing letters. However, these devices often fail between six months and one year. The longest BCI in use lasted seven years. Even then, issues like inflammation, scarring, and programmed cell death (apoptosis) undermine performance over time.
Hemostemix's Innovative Cell-Based SolutionThe article proposes using two types of autologous (patient-derived) progenitor cells: Angiogenic Cell Precursors (ACP-01, VesCell™) and Neural Cell Precursors (NCP-01), delivered into the cerebrospinal fluid, to foster a healing cellular environment around the implant.
ACP-01 (VesCell™) produces signals like IL-8, VEGF, and angiogenin. They attract natural killer (NK) cells that suppress inflammation, reduce tissue scarring, and support new blood vessel growth (angiogenesis).
ACP-01potentiate healing through the expression of tissue regeneration factors CXCL8, VEGF, and angiogenin. They include CD34+ (blood stem cell). CXCL8 recruit endogenous CD34+, that circulate peripherally, to the site of implant.
CXCL8 (interleukin-8) activate NF-κB, resulting in gene transcription and protein synthesis necessary for learning (memory formation and consolidation).
NCP- 01express receptors like CXCR4, and migrate toward the BCI site. NCP help shift immune cells into a neuroprotective (M2) state. NCP differentiate into neurons and supporting glial cells that promote new synaptic connections and neural plasticity.
Figure 1. Natural Killer (NK) cells recruited by angiogenic cell precursors (ACPs) suppress inflammation through the release of anti-inflammatory cytokines, dendritic cell and monocyte maturation, and lysis of auto-aggressive T cells. Created in BioRender. Tuchman, K. (2025) https://biorender.com/6rfoaivTo view an enhanced version of this graphic, please visit:https://images.newsfilecorp.com/files/5065/260846_d1729e68f4832a43_001full.jpg
Figure 2. Angiogenic cell precursors (ACPs) potentiate healing through expression of tissue regeneration factors such as the chemokine interleukin-8 (CXCL8), vascular endothelial growth factor (VEGF) and angiogenin. In addition to the robust presence of CD34+ in ACPs, the expressed CXCL8 recruits peripheral CD34+ precursor cells, further supporting angiogenesis. Created by BioRender. Tuchman, K. (2025) https://biorender.com/w2cthsgTo view an enhanced version of this graphic, please visit:https://images.newsfilecorp.com/files/5065/260846_d1729e68f4832a43_002full.jpg
Figure 3. Interleukin-8 (CXCL8) is expressed by angiogenic cell precursors (ACPs), and activatesthe canonical NF-κB pathway, resulting in gene transcription and protein synthesis necessary formemory formation and consolidation. Created in BioRender. Tuchman, K. (2025) https://BioRender.com/u2icrk5To view an enhanced version of this graphic, please visit:https://images.newsfilecorp.com/files/5065/260846_d1729e68f4832a43_003full.jpg
Mechanism of Action
Together, ACP and NCP support a cascade of beneficial molecular events:
Activation of neurotrophic factors and NF-κB pathways that protect cells (anti-apoptosis).
Promotion of synaptogenesis (formation of connections between neurons), neuritogenesis (growth of neural processes), to improve learning-related plasticity.
As the patient's DNA-based engineered cellular environment, ACP and NCP home to the site of BCI, decrease inflammation, increase angiogenesis, increase neuro-protectiveness, promote new synaptic connections, and may dramatically extend both the lifespan of BCI, signal fidelity and learning.
Why This Matters to Hemostemix
Hemostemix's patented proprietary platform produces ACP-01 (angiogenic precursors) and NCP-01 (neural precursors) from a patient's own blood. This new research provides a scientific basis of how the combination of ACP-01+NCP-01 promises to overcome the major limitations in BCI implants.
The findings align with Hemostemix's vision of licensing ACP-01 and NCP-01 to enhance BCI longevity and functionalities.
Forward-Looking Perspective
This research paves the way for:
Licensing with BCI technology companies to combine autologous stem-cell support of BCI with cutting-edge patient-based angiogenic and neural interfaces.
Rapid preclinical and clinical testing of ACP-01 + NCP-01 at BCI implant sites.
"We imagine a world where the environment for BCI, the patient's brain, augmented by the patients' own stem cells, improves the longevity of the implants from months to a lifetime, improves signal fidelity to increase functional movement, and increases learning and memory retention," stated Dr. Fraser Henderson, lead author.
"I want to thank Dr. Henderson and Ms. Tuchman for this very thorough exposition of the benefits of using one's own DNA structured as ACP & NCP to improve BCIs. Truly, this is incredible work. Coupled with our market analyses of the top three BCI companies, shareholders can expect more news to follow, as Mr. Lawrence, Chief Commercialization Officer and I meet with potential partners," stated Thomas Smeenk, CEO.
In Summary
Dr. Henderson has outlined a new cell-based approach that may allow brain implants to work reliably for years. By delivering two types of the patient's blood-derived stem cell precursors—one that fights inflammation and boosts blood flow, the other that helps build new neuronal cells—this method could protect and improve the brain at the site of BCI implant. Hemostemix's ready-to-use cell products (ACP-01 and NCP-01) are a direct fit for this approach and could potentially transform how long and well brain-computer interfaces function.
ABOUT HEMOSTEMIX
Founded in 2003, Hemostemix is a stem-cell therapeutics company with patented technology to generate autologous angiogenic and neural cell precursors from patient blood. Its ACP-01 and NCP-01 cell lines aim to treat cardiovascular, neurological, and implant-related conditions. A winner of the World Economic Forum Technology Pioneer Award, the Company has developed, patented, is scaling and selling autologous (patient's own) blood-based stem cell therapy, VesCell™ (ACP-01). Hemostemix has completed seven clinical studies of 318 subjects and published its results in 11 peer reviewed publications. ACP-01 is safe, clinically relevant and statistically significant as a treatment for peripheral arterial disease, chronic limb threatening ischemia, non ischemic dilated cardiomyopathy, ischemic cardiomyopathy, congestive heart failure, and angina. Hemostemix completed its Phase II clinical trial for chronic limb threatening ischemia and published its results in the Journal of Biomedical Research & Environmental Science. As compared to a five year mortality rate of 60% in the CLTI patient population, UBC and U of T reported to the 41st meeting of vascular surgeons: 0% mortality, cessation of pain, wound healing in 83% of patients followed for up to 4.5 years, as a midpoint result. For more information, please visit www.hemostemix.com.
For further information, please contact: Thomas Smeenk, President, CEO & Co-Founder: EM: tsmeenk@hemostemix.com / PH: 905-580-4170
Neither the TSX Venture Exchange nor its Regulation Service Provider (as that term is defined under the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Forward-Looking Information: This news release contains "forward-looking information" within the meaning of applicable Canadian securities legislation. All statements, other than statements of historical fact, included herein are forward-looking information. In particular, this news release contains forward-looking information in relation to the publication in CELLS of the properties of ACP-01+NCP-01 and the improvement of brain computer interface (BCI) technologies. There can be no assurance that such forward-looking information will prove to be accurate. Actual results and future events could differ materially from those anticipated in such forward-looking information. This forward-looking information reflects Hemostemix's current beliefs and is based on information currently available to Hemostemix and on assumptions Hemostemix believes are reasonable. These assumptions include, but are not limited to: the underlying value of Hemostemix and its Common Shares; the successful resolution of any litigation that Hemostemix is pursuing or defending (the "Litigation"); the results of ACP-01 research, trials, studies and analyses, including the analysis being equivalent to or better than previous research, trials or studies; the receipt of all required regulatory approvals for research, trials or studies; the level of activity, market acceptance and market trends in the healthcare sector; the economy generally; consumer interest in Hemostemix's services and products; competition and Hemostemix's competitive advantages; and, Hemostemix obtaining satisfactory financing to fund Hemostemix's operations including any research, trials or studies, and any Litigation. Forward-looking information is Subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of Hemostemix to be materially different from those expressed or implied by such forward-looking information. Such risks and other factors may include, but are not limited to: the ability of Hemostemix to complete clinical trials, complete a satisfactory analyses and file the results of such analyses to gain regulatory approval of a phase II or phase III clinical trial of ACP-01; potential litigation Hemostemix may face; general business, economic, competitive, political and social uncertainties; general capital market conditions and market prices for securities; delay or failure to receive board or regulatory approvals; the actual results of future operations including the actual results of future research, trials or studies; competition; changes in legislation affecting Hemostemix; the timing and availability of external financing on acceptable terms; long-term capital requirements and future developments in Hemostemix's markets and the markets in which it expects to compete; lack of qualified, skilled labour or loss of key individuals; and risks related to the COVID-19 pandemic including various recommendations, orders and measures of governmental authorities to try to limit the pandemic, including travel restrictions, border closures, non-essential business closures service disruptions, quarantines, self-isolations, shelters-in-place and social distancing, disruptions to markets, disruptions to economic activity and financings, disruptions to supply chains and sales channels, and a deterioration of general economic conditions including a possible national or global recession or depression; the potential impact that the COVID-19 pandemic may have on Hemostemix which may include a decreased demand for the services that Hemostemix offers; and a deterioration of financial markets that could limit Hemostemix's ability to obtain external financing. A description of additional risk factors that may cause actual results to differ materially from forward-looking information can be found in Hemostemix's disclosure documents on the SEDAR website at www.sedarplus.ca. Although Hemostemix has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. Readers are cautioned that the foregoing list of factors is not exhaustive. Readers are further cautioned not to place undue reliance on forward-looking information as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Forward-looking information contained in this news release is expressly qualified by this cautionary statement. The forward-looking information contained in this news release represents the expectations of Hemostemix as of the date of this news release and, accordingly, it is Subject to change after such date. However, Hemostemix expressly disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as expressly required by applicable securities law.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/260846
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Skift
12 minutes ago
- Skift
'Never Seen a Drop Like This:' U.S. Politics Drive Meeting Attendees Away
The sharp decline in global attendance at a recent international medical congress is more than a one-off, it's a red flag. As political rhetoric escalates, the U.S. is becoming a less viable destination for truly international meetings. Attendance at the International Society on Thrombosis and Haemostasis Congress in Washington, D.C. this June fell well below expectations, a warning to organizers who rely on the U.S. as a global meetings hub. The group expected 6,000 attendees, but just 4,500 showed up. Canadian participation alone plummeted 55% from the 2023 meeting in Montreal, while attendance from the UK, France, and the Netherlands was down nearly 30%. An additional 500 U.S.-based registrants was not enough to compensate for the decline in international participation. 'We have never seen a drop like this,' said Thomas Reiser, executive director of ISTH. 'Our numbers are very low for a truly international congress.' In total, 55% of attendees came from outside the U.S., a drop from the typical 75%. U.S. Political Climate a Deterrent A mix of factors drove the decline, said Reiser. The biggest was a growing discomfort with the U.S. political environment. In addition, some European countries as well as Canada have issued advisories for travelers to the U.S., and some international scientific organizations have recommended against sending researchers to the U.S., said Resier. 'U.S. politics, more so than geopolitics, although the Middle East conflict also played a role, particularly with the U.S.'s greater involvement in the weeks before the congress had an impact. We received information from quite a few members in particular, Canada, the UK, and Western Europe, typically some of the strongest membership and registration countries, that either they themselves did not feel comfortable attending or their institutions had travel advisories, including recommendations not to go to the U.S.,' said Reiser. Although actual travel and border entry went smoothly for those who attended, perception damage had already been done. 'Media reports about possible questioning, detentions, and refusal of entry into the U.S. did not help,' he said. Revenue Takes a Hit The consequences are not just a decline in attendees. 'We heard from several participants, exhibitors, and sponsors that they would have expected higher numbers overall,' said Reiser. 'With an overall reduction in numbers of an estimated 20 to 25%, this of course has a significant financial impact on the meeting and the society. This may also have a bit of an impact on future congresses, if sponsors and exhibitors believe our registration numbers are closer to 4,500 than 6,000.' Next year's meeting will be in Paris. The 2027 meeting, which should be in North America due to event rotation, is under review. 'We're in the midst of considering whether the U.S. is the right destination for an international meeting like ours,' Reiser said. 'It's an unfortunate situation. The way the U.S. is perceived is having a real impact in the scientific space.'
Yahoo
2 hours ago
- Yahoo
Zero Candida Technologies to Present at the OTCQB Venture Virtual Investor Conference on August 7th
Company invites individual and institutional investors, as well as advisors and analysts, to attend online at VANCOUVER, British Columbia, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Zero Candida Technologies, Inc. (TSXV: ZCT) (OTCQB: ZCTFF) (FSE: 9L2) (the "Company" or "ZCT"), a medical device company developing a SMART, AI-driven FemTech device to revolutionize women's health, today announced that Sophya Galper Komet, CFO, and Dr. Asher Holzer, Founder, will present live at the OTCQB Venture Virtual Investor Conference hosted by on August 7th , 2025. DATE: August 7th TIME: 12:00 PM ETLINK: REGISTER HEREAvailable for 1x1 meetings: August 7 & 8, 2025 This will be a live, interactive online event where investors are invited to ask the Company questions in real-time. If attendees are not able to join the event live on the day of the conference, an archived webcast will also be made available after the event. It is recommended that online investors pre-register and run the online system check to expedite participation and receive event updates. Learn more about the event at Company Highlights Demonstrated 99.999% Candida elimination in 3 hours during POC testing, targeting FDA De Novo regulatory pathway Expanding global IP portfolio with patents filed in Europe, the United States, Brazil, and fully granted in South Africa Cross-listed on FSE and OTCQB, including recent DTC eligibility, broadening investor access In active discussions with major hospitals and U.S. pharmaceutical companies to support future clinical trials and commercialization About Zero Candida Technologies Zero Candida Technologies, Inc. is a publicly traded FemTech company pioneering innovative solutions to address unmet needs in women's health. The Company is developing a SMART, tampon-like device that combines artificial intelligence and therapeutic blue light at a precise wavelength and intensity to effectively treat Vulvo-Vaginal Candidiasis (VVC) through personalized, at-home care. This condition affects approximately 75% of women worldwide, and recurrent cases (four or more episodes per year) are increasingly resistant to existing drug treatments, as the root cause remains poorly understood and inadequately addressed. With the VVC treatment market projected to exceed US $2B by 2030, Zero Candida is combining hybrid medicine and technology-based diagnostics to improve access for underserved populations and bring gynecology into the 21st century. To learn more, visit About Virtual Investor Conferences®Virtual Investor Conferences (VIC) is the leading proprietary investor conference series that provides an interactive forum for publicly traded companies to seamlessly present directly to investors. Providing a real-time investor engagement solution, VIC is specifically designed to offer companies more efficient investor access. Replicating the components of an on-site investor conference, VIC offers companies enhanced capabilities to connect with investors, schedule targeted one-on-one meetings and enhance their presentations with dynamic video content. Accelerating the next level of investor engagement, Virtual Investor Conferences delivers leading investor communications to a global network of retail and institutional investors. CONTACTS:Zero Candida Technologies, Inc.+1 (647) 874-3767 investors@ Virtual Investor Conferences John M. ViglottiSVP Corporate Services, Investor AccessOTC Markets Group (212) 220-2221johnv@
Medscape
3 hours ago
- Medscape
Keep Canada's Health Data Safe and in Canada, Experts Say
Canada must move quickly to safeguard its health data, experts say, adding that the need has become urgent in today's changing political climate. 'Health data are critical to health systems in Canada, but the potential of these data to be accessed and used by foreign entities for surveillance purposes without consent is concerning,' Michael Geist, professor of law and Canada research chair of internet and e-commerce law at the University of Ottawa, Ottawa, and coauthors wrote in a commentary published on July 28 in the Canadian Medical Association Journal. Kumanan Wilson, MD 'Health data are going to be extremely valuable going forward, not just for the provision of care, but also for the emerging health artificial intelligence [AI] industry,' co-author Kumanan Wilson, MD, CEO of Bruyère Health Research Institute and internal medicine specialist at the Ottawa Hospital, Ottawa, told Medscape Medical News . A Multipronged Approach Canada's health system mostly relies on US providers to manage electronic medical record systems for hospitals. These providers store encrypted data on servers that, though in Canada, are owned by US companies. 'We need to develop a sovereign Canadian cloud server, and that will take time, because it will have to provide the same functionality as the American servers. Those companies are giants because they are very good at what they do. Our ability to meet the standards that they provide is not here now,' he added. The US currently can use Canadian health data. 'For example, the recent US Clarifying Lawful Overseas Use of Data Act allows US law enforcement to access data held by US companies in other countries and could be a threat. We would rather see the US be unable to use our data. Canadian companies must have access in a privacy-secure way to support Canadian industry,' said Wilson. 'We also need to have AI algorithms that are based on our population. We can't be importing an algorithm built in the US and applying it to the Canadian population, because it's not the same as our population,' Wilson added. The authors suggest the following multipronged approach to addressing these issues: Ensure that health data are secure by requiring encryption by default. Require health data to be hosted on Canadian soil. Strengthen Canadian privacy laws against the disclosure of data to foreign countries without consent. Invest in and support the creation of Canadian cloud servers to ensure that data are held in Canada by Canadian providers. Encryption: No Panacea Victoria Lemieux, PhD, professor of archival science at the University of British Columbia in Vancouver, agrees that Canadian health data must be protected. But she is not convinced by the solutions that the authors have proposed. Victoria Lemieux, PhD 'Encryption does not solve the problem entirely, as we are now on the brink of quantum computing that has the potential to break standard encryption,' Lemieux told Medscape Medical News . 'Overreliance on encryption as a solution risks overlooking the need to ensure that all encryption used is quantum-safe. Rather than recommending encryption as a solution, I would prefer to see a recommendation that a range of privacy-enhancing technologies be employed to protect our health and other data,' Lemieux said. However, she does support investment in a Canadian cloud infrastructure. 'We face the same issue that Europe does, since we have become overly reliant on US technology firms. If we don't hold and store the data in Canada on Canadian servers run by Canadian companies, then we aren't really in control,' said Lemieux. 'A partnership with European cloud providers might help us move away from our reliance on US tech and help us develop secure and scalable alternatives.' Health data can be kept in the locations where it originates and be shared freely, when necessary, Lemieux continued. 'I have developed such technology, which currently is applied to archives and cultural heritage, but there's no reason it cannot be applied in healthcare as well.' But focusing on cloud technology development overlooks Canada's overreliance on US tech firms for AI, Lemieux noted. 'We need to ensure that the models we are using preserve privacy, comply with our Canadian values and how we want our data to be used, and do not divulge sensitive Canadian data to unauthorized parties,' she said. 'AI bots, whether from the US, China, or elsewhere, should not be allowed to range freely over our data, extracting value and information that does not come back to benefit Canadians. We must do more to protect ourselves from these bad data practices,' Lemieux added. More protection in Canadian privacy laws about disclosure to foreign jurisdictions is needed, said Lemieux, but these laws must be strengthened for the digital age. 'A law is only as good as a government's willingness to enforce it. If we take the recent Canadian government's bowing down to the US on the Digital Services Tax [a 3% tax on certain revenues of large digital service providers], I question whether we have the geopolitical clout to enforce such laws. But that's not an argument not to put the laws in place. We're better with them than without them.'
